Pemvidutide
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Pemvidutide
- alt 801
- ALT-801
- md 1373
- MD-1373
- md1373
- MD1373
- pemvidutida
- Pemvidutida
- pemvidutide
- Pemvidutide
- pemvidutide [INN]
- PEMVIDUTIDE [USAN]
- Pemvidutide [WHO-DD]
- pemvidutide inn
- pemvidutide usan
- pemvidutide who dd
- sp 1373
- SP-1373
- sp1373
- SP1373
- CAS registry numbers
- 2538014-94-5
- ChEMBL ID
- CHEMBL5095142
- FDA ingredient codes (UNII)
- A35F525WBG
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tide
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Obesity
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001249
- Subject identifier
- D065626
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Urethral Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004192
- Subject identifier
- D014523
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001378
- Condition identifier
- EFO_0003095
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008573
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001249
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- HP_0025502
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002046
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002691
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005059
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005627
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007576
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 1
And 5 more, listed on the interactive page.
- NCT00496860
- NCT01029873
- NCT01326871
- NCT01478074
- NCT01625260
- NCT01670994
- NCT04561245
- NCT04972396
- NCT05006885
- NCT05292911
- NCT05134662
- NCT05295875
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- HXQGTFTSDYSKYLDEKAAKEFIQWLLQT
- Component
- Disulfide bridges
- Sequence
- 16-20
Related records
Trials (15)
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
- ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
- ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
- Efficacy and Safety of ALT-801 in the Treatment of Obesity
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
- Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
- QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
- Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
In development for (13)
- Acute myeloid leukemia Phase 1
- Acute myeloid leukemia by FAB classification Phase 2
- Alcoholic liver disease Phase 2
- Cancer Phase 1
- Metabolic dysfunction-associated steatohepatitis Phase 1
- Metabolic dysfunction-associated steatotic liver disease Phase 1
- Metastatic melanoma Phase 1
- Obesity disorder Phase 2
- Plasma cell myeloma Phase 1
- Type 2 diabetes mellitus Phase 1
- Urethra cancer Phase 1
- Urinary bladder cancer Phase 1
- Urinary bladder carcinoma Phase 2